Stephen Williamson Byers

US Patent:

6433149, Aug 13, 2002

Filed:

May 5, 1999

Appl. No.:

09/305927

Inventors:

Orest W. Blaschuk - Westmount, CA
James Matthew Symonds - Ottawa, CA
Stephen Byers - Washington DC
Barbara J. Gour - Kemptville, CA

Assignee:

Adherex Technologies, Inc. - Ottawa

International Classification:

A61M 138

US Classification:

530412, 530300, 530328, 530345, 530413, 530810, 530828, 604 501, 604 502, 604 601, 4241551, 4241851, 4242271, 435 2, 435 71

Abstract:

Agents for inhibiting cancer metastasis are provided. The methods comprise administering to a patient an antimetastatic agent that comprises one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.

US Patent:

6593297, Jul 15, 2003

Filed:

Mar 8, 1999

Appl. No.:

09/264516

Inventors:

Orest W. Blaschuk - Westmount, CA
James Matthew Symonds - Ottawa, CA
Stephen Byers - Washington DC
Barbara J. Gour - Kemptville, CA

Assignee:

Adherex Technologies, Inc. - Ottawa

International Classification:

A61K 31395

US Classification:

514 12, 514 9, 514 11, 514 13, 514 14, 514 15, 514 16, 514 17, 4241301

Abstract:

Agents for inhibiting cancer metastasis are provided. The methods comprise administering to a patient an antimetastatic agent that comprises one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.

US Patent:

6677116, Jan 13, 2004

Filed:

Apr 14, 2000

Appl. No.:

09/551976

Inventors:

Orest W. Blaschuk - Westmount, CA
Stephen Byers - Washington DC
Barbara J. Gour - Kemptville, CA

Assignee:

Adherex Technologies, Inc. - Ottawa

International Classification:

C12Q 168

US Classification:

435 6, 530300, 514 9, 514 14, 514 2, 536 221

Abstract:

Modulating agents for inhibiting -catenin mediated gene expression are provided. The modulating agents comprise one or more of: (1) the peptide sequence LXXLL (SEQ ID NO:1); or (2) a peptide analogue or peptidomimetic thereof. Methods for using such modulating agents for modulating -catenin mediated gene expression and cellular differentiation in a variety of contexts (e. g. , for modulating hair growth or treating cancer or Alzheimers disease) are provided.

US Patent:

6680175, Jan 20, 2004

Filed:

Jan 20, 1999

Appl. No.:

09/234395

Inventors:

Orest W. Blaschuk - Westmount, CA
James Matthew Symonds - Ottawa, CA
Stephen Byers - Washington DC
Barbara J. Gour - Montreal, CA

Assignee:

Adherex Technologies, Inc. - Ottawa

International Classification:

G01N 33574

US Classification:

435 723, 435 71, 435 721, 435 72

Abstract:

Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.

US Patent:

6682901, Jan 27, 2004

Filed:

May 5, 1999

Appl. No.:

09/305928

Inventors:

Orest W. Blaschuk - Westmount, CA
James Matthew Symonds - Ottawa, CA
Stephen Byers - Washington DC
Barbara J. Gour - Kemptville, CA

Assignee:

Adherex Technologies, Inc. - Ottawa

International Classification:

G01N 33574

US Classification:

435 723, 435 71, 435 72

Abstract:

Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.

US Patent:

7481999, Jan 27, 2009

Filed:

Dec 3, 2004

Appl. No.:

11/003150

Inventors:

Orest W. Blaschuk - Westmont, CA
Barbara J. Gour - Kemptville, CA
James Matthew Symonds - Durham NC, US
Stephen Byers - Washington DC, US

Assignee:

Adherex Technologies, Inc. - Ottawa

International Classification:

A61K 39/395
C07K 16/18

US Classification:

4241301, 4241391, 5303871, 5303879, 5303881

Abstract:

Compositions and methods for modulating OB-cadherin-mediated functions are provided. The compositions and methods employ OB-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.

US Patent:

20030096746, May 22, 2003

Filed:

May 7, 2002

Appl. No.:

10/141357

Inventors:

Orest Blaschuk - Westmount, CA
James Symonds - Ottawa, CA
Stephen Byers - Washington DC, US
Barbara Gour - Kemptville, CA

Assignee:

Adherex Technologies, Inc. - Ottawa ON

International Classification:

A61K038/16
A61K038/10
A61K038/08
A61K038/06
A61K038/05

US Classification:

514/012000, 514/013000, 514/014000, 514/015000, 514/016000, 514/017000, 514/018000

Abstract:

Agents for inhibiting cancer metastasis are provided. The methods comprise administering to a patient an antimetastatic agent that comprises one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof

US Patent:

20040142854, Jul 22, 2004

Filed:

Oct 21, 2003

Appl. No.:

10/691462

Inventors:

Orest Blaschuk - Westmount, CA
Stephen Byers - Washington DC, US
Barbara Gour - Kemptville, CA

Assignee:

Adherex Technologies, Inc. - Ottawa

International Classification:

A61K038/16

US Classification:

514/007000

Abstract:

Modulating agents for inhibiting degradation of cytoplasmic -catenin are provided. The modulating agents comprise one or more of: (1) the peptide sequence SYLDS(PO)GIHS(PO)G (SEQ ID NO:1) or (2) a peptide analogue or peptidomimetic thereof. Methods for using such modulating agents for stimulating -catenin mediated gene expression and cellular differentiation are provided.